Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GB:0MGB)
LSE:0MGB
0MGB Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1,268.00 - kr2,123.00
Previous CloseN/A
Volume5.49K
Average Volume (3M)30.29K
Market Cap
kr85.16B
Enterprise Valuekr75.38B
Total Cash (Recent Filing)kr9.86B
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)10.6
Beta0.60
Next Earnings
May 08, 2025EPS Estimate
15.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)122.59
Shares Outstanding66,197,240
10 Day Avg. Volume56,689
30 Day Avg. Volume30,288
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)N/A
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr1,981.38Price Target Upside52.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Competitive PositioningGenmab is confident in surpassing competition benchmarks with Rina-S, backed by compelling data presented in ovarian cancer trials.
Pipeline And InnovationManagement is focusing on pipeline assets, providing peak sales guidance and clearer commentary on data.
Stock RecommendationAnalyst reiterates a BUY rating with a price objective significantly higher than the current price, indicating confidence in stock growth.
Bears Say
Investor ConcernsSome investor questions are expected to persist around the profile of data in a small PII.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.01%
Mutual Funds
<0.01% Other Institutional Investors
78.85% Public Companies and
Individual Investors
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1268.00 and its highest was kr2123.00 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is kr85.16B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 12, 2025. The company reported kr60.08 earnings per share for the quarter, beating the consensus estimate of kr26.701 by kr33.379.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 15.26.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,197,240 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr60.08 in its last earnings report, beating expectations of kr26.701. Following the earnings report the stock price went up 0.214%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
---
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
0MGB Stock 12 Month Forecast
Average Price Target
kr1,981.38
▲(52.80% Upside)
Technical Analysis
Best Analysts Covering 0MGB
1 Year
1 Year Success Rate
18/38 ratings generated profit
1 Year Average Return
+8.46%
reiterated a buy rating 22 days ago
Copying Emily Field's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +8.46% per trade.
---